Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial, which assessed the noninferiority of subcutaneous pembrolizumab, Merck’s anti-PD-1 therapy, combined with chemotherapy, versus intravenous (IV) KEYTRUDA…
Celltrion presented new findings from Phase III randomized controlled trials (RCTs) for its biosimilar candidates CT-P41 (referencing PROLIA®/XGEVA® for postmenopausal osteoporosis) and CT-P47 (referencing ACTEMRA® for moderate-to-severe rheumatoid arthritis) at the American College of Rheumatology (ACR) Convergence 2024 in Washington,…
As world leaders gather in Rio de Janeiro, Brazil, for the G20 Summit this weekend, the city’s iconic Christ the Redeemer statue will be bathed in teal light in a symbolic show of support for the global fight against cervical…
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced that the European Medicines Agency’s…
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 medication and introduced a GLP-1 Supply Tracker, where individuals…
QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed…
Business Leaders and Industry Experts Join Top Policymakers to Address Pivotal Issues in Health Globally at the Milken Institute 2024 Future of Health Summit The Milken Institute 2024 Future of Health Summit opens today, gathering hundreds of renowned business leaders, health experts,…
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV…
VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership with Neurochase, the CNS (central nervous system) delivery platform specialist, to manufacture electrospun micro-catheters to deliver advanced therapies to the brain.UK-based Neurochase is a medical technology company developing a…
AstraZeneca and Amgen announced promising top-line results from the Phase III WAYPOINT trial, showing that Tezspire (tezepelumab) significantly reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo. The WAYPOINT trial, a…
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is gearing up for the sixth annual BOTOX® Cosmetic Day, set for Wednesday, November 20, 2024. This special day celebrates the healthcare providers and patients who have helped make BOTOX® Cosmetic the world’s…
Second Round of Polio Vaccination Campaign in Gaza Completed Amid Ongoing Conflict: UNICEF and WHO The second round of the polio vaccination campaign in the Gaza Strip concluded yesterday, with 556,774 children under the age of 10 receiving a second…